Title:
COMPOSITIONS AND METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AN INHIBITOR OF ENDOTHELIN RECEPTOR ACTIVITY
Document Type and Number:
WIPO Patent Application WO2001000198
Kind Code:
A3
Abstract:
Described herein are results which show that an endothelin receptor antagonist, BQ788, increases pigmentation and significantly reduces the viability of 7 human melanoma cell lines in culture. Moreover, it is described herein that administration of BQ788 significantly slows melanoma tumor growth in nude mice, including a complete growth arrest in half of the mice treated systemically. Thus, inhibitors of endothelin receptor activity are described herein as beneficial for the treatment of cancer.
Inventors:
PATTERSON PAUL H
LAHAV RONIT
LAHAV RONIT
Application Number:
PCT/US2000/018215
Publication Date:
October 31, 2002
Filing Date:
June 29, 2000
Export Citation:
Assignee:
CALIFORNIA INST OF TECHN (US)
International Classes:
A61K38/06; A61K38/22; A61K47/48; A61P35/00; (IPC1-7): A61K45/00; A61K38/06; A61P35/00
Domestic Patent References:
| WO2000036918A1 | 2000-06-29 | |||
| WO1998041206A1 | 1998-09-24 |
Other References:
LAHAV, RONIT ET AL: "An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (SEPT. 28, 1999) VOL. 96, NO. 20, PP. 11496-11500., XP001026099
KIKUCHI K ET AL: "DECREASED ETB RECEPTOR EXPRESSION IN HUMAN METASTATIC MELANOMA CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 219, no. 3, 1996, pages 734 - 739, XP002931328, ISSN: 0006-291X
GIRALDI T ET AL: "PRIMARY TUMOR GROWTH AND FORMATION OF SPONTANEOUS LUNG METASTASES IN MICE BEARING LEWIS CARCINOMA TREATED WITH PROTEINASE INHIBITORS.", ANTICANCER RES, (1984) 4 (4-5), 221-224., XP000646515
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; TUERK, I. ET AL: "Inhibition of growth of prostate cancer cell lines by endothelin receptor antagonists.", XP002184315, retrieved from STN
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; CARDUCCI, MICHAEL A. (1) ET AL: "Endothelin receptor antagonist, ABT-627, for prostate cancer: Initial trial results.", XP002184316, retrieved from STN
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; CARDUCCI, M. A. (1) ET AL: "Phase I clinical results of ABT - 627, an endothelin receptor antagonist, for refractory adenocarcinomas.", XP002184317, retrieved from STN
KROODSMA J.M. ET AL: "[Endothelins: Possibly a new approach to pharmacotherapy of cardiovascular diseases, renal diseases and oncological conditions]. ENDOTHELINEN: MOGELIJK EEN NIEUW FARMACOLOGISCH AANGRIJPINGSPUNT BIJ HART- EN VAATZIEKTEN, NIERZIEKTEN EN ONCOLOGISCHE AANDOENINGEN.", NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, (1997) 141/38 (1806-1810)., XP002070362
MORAITIS, S. ET AL: "Endothelin expression and responsiveness in human ovarian carcinoma cell lines.", EUROPEAN JOURNAL OF CANCER, (1997) VOL. 33, NO. 4, PP. 661-668., XP004282572
JANUS, T. J. ET AL: "ABT-627, endothelin-receptor antagonist, for advanced cancer: Phase I pharmacokinetic results.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 90-91. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICA, XP001026083
KIKUCHI K ET AL: "DECREASED ETB RECEPTOR EXPRESSION IN HUMAN METASTATIC MELANOMA CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 219, no. 3, 1996, pages 734 - 739, XP002931328, ISSN: 0006-291X
GIRALDI T ET AL: "PRIMARY TUMOR GROWTH AND FORMATION OF SPONTANEOUS LUNG METASTASES IN MICE BEARING LEWIS CARCINOMA TREATED WITH PROTEINASE INHIBITORS.", ANTICANCER RES, (1984) 4 (4-5), 221-224., XP000646515
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; TUERK, I. ET AL: "Inhibition of growth of prostate cancer cell lines by endothelin receptor antagonists.", XP002184315, retrieved from STN
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; CARDUCCI, MICHAEL A. (1) ET AL: "Endothelin receptor antagonist, ABT-627, for prostate cancer: Initial trial results.", XP002184316, retrieved from STN
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; CARDUCCI, M. A. (1) ET AL: "Phase I clinical results of ABT - 627, an endothelin receptor antagonist, for refractory adenocarcinomas.", XP002184317, retrieved from STN
KROODSMA J.M. ET AL: "[Endothelins: Possibly a new approach to pharmacotherapy of cardiovascular diseases, renal diseases and oncological conditions]. ENDOTHELINEN: MOGELIJK EEN NIEUW FARMACOLOGISCH AANGRIJPINGSPUNT BIJ HART- EN VAATZIEKTEN, NIERZIEKTEN EN ONCOLOGISCHE AANDOENINGEN.", NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, (1997) 141/38 (1806-1810)., XP002070362
MORAITIS, S. ET AL: "Endothelin expression and responsiveness in human ovarian carcinoma cell lines.", EUROPEAN JOURNAL OF CANCER, (1997) VOL. 33, NO. 4, PP. 661-668., XP004282572
JANUS, T. J. ET AL: "ABT-627, endothelin-receptor antagonist, for advanced cancer: Phase I pharmacokinetic results.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 90-91. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICA, XP001026083
Download PDF: